Board Committees

Bill Wyman is an advisor to corporate management teams in the pharmaceutical, finance and technology industries.  He has served on some twenty-five Boards of Directors and Advisory Boards of both public and private companies.  Prior to his advisory work, he co-founded Oliver Wyman & Company, today a leading global management consulting firm.  Before founding Oliver Wyman, he was with Booz Allen and Hamilton (New York, Duesseldorf, Athens) as President and Managing Partner of Management Consulting Group, member of the Executive Committee and the Board of Directors.  He received his BA from Colgate University, and an MBA from Harvard. Following his graduation from Colgate, he served four years in the U.S. Navy.

Senior partner at Kirwin LLP, has been advising and representing businesses in a range of industries and sizes from local to multinational for over 30 years. He obtained his BA in Economics (First Class Standing) from the University of Alberta in 1978 followed by his JD from the University of Toronto, Faculty of law in 1982. He practiced initially with the Canadian Federal Department of Justice from 1982 to 1986 then founded the predecessor to Kirwin LLP where he currently practices in Edmonton, Alberta.

Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. He is also a co-founder and board member for Vico Therapeutics, an oligonucleotide-based RNA modulating Company focused on developing therapeutics for patients suffering from rare CNS disorders.
Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise, overseeing seminal investments to enter the ophthalmology field and advancing Biogen’s gene therapy strategy. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.
Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Maggie has almost 30 years of experience providing intellectual property advice to the biotechnology and pharmaceutical industries.  She holds a B.A. in Biology from University of California, a Ph.D. in Molecular Biology and Virology from Cornell University Graduate School of Medical Sciences and a J.D. summa cum laude from New York Law School.  After spending 8 years at the boutique IP firm of Fish & Neave in New York, Maggie spent 14 years at Genzyme, where she ultimately became Sr. Vice President and Chief Patent Counsel.  In that role, she was responsible for providing strategic guidance and IP advice for major commercial and research transactions as well as for developing and implementing strategies to procure, license, defend and enforce Genzyme’s worldwide intellectual property.  Upon Genzyme’s acquisition by Sanofi, Maggie became Vice President and Chief Patent Counsel at Sanofi Pasteur, where she was responsible for leading IP attorneys and agents in the U.S., Canada, France and India.   In 2014, Maggie became an independent IP consultant, providing strategic advice related to IP portfolio development, commercial transactions and potential and ongoing patent and trade secret disputes.

Bill Wyman is an advisor to corporate management teams in the pharmaceutical, finance and technology industries.  He has served on some twenty-five Boards of Directors and Advisory Boards of both public and private companies.  Prior to his advisory work, he co-founded Oliver Wyman & Company, today a leading global management consulting firm.  Before founding Oliver Wyman, he was with Booz Allen and Hamilton (New York, Duesseldorf, Athens) as President and Managing Partner of Management Consulting Group, member of the Executive Committee and the Board of Directors.  He received his BA from Colgate University, and an MBA from Harvard. Following his graduation from Colgate, he served four years in the U.S. Navy.

Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. He is also a co-founder and board member for Vico Therapeutics, an oligonucleotide-based RNA modulating Company focused on developing therapeutics for patients suffering from rare CNS disorders.
Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise, overseeing seminal investments to enter the ophthalmology field and advancing Biogen’s gene therapy strategy. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.
Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Senior partner at Kirwin LLP, has been advising and representing businesses in a range of industries and sizes from local to multinational for over 30 years. He obtained his BA in Economics (First Class Standing) from the University of Alberta in 1978 followed by his JD from the University of Toronto, Faculty of law in 1982. He practiced initially with the Canadian Federal Department of Justice from 1982 to 1986 then founded the predecessor to Kirwin LLP where he currently practices in Edmonton, Alberta.

Bill Wyman is an advisor to corporate management teams in the pharmaceutical, finance and technology industries.  He has served on some twenty-five Boards of Directors and Advisory Boards of both public and private companies.  Prior to his advisory work, he co-founded Oliver Wyman & Company, today a leading global management consulting firm.  Before founding Oliver Wyman, he was with Booz Allen and Hamilton (New York, Duesseldorf, Athens) as President and Managing Partner of Management Consulting Group, member of the Executive Committee and the Board of Directors.  He received his BA from Colgate University, and an MBA from Harvard. Following his graduation from Colgate, he served four years in the U.S. Navy.